Myeloma/Myelodysplastic Cancer

Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients with Multiple Myeloma who have Completed a Dexamethasone-Based Induction Regimen [ECOG 1A05]

Principal Investigator:
Elyse Schneiderman, MD
Contact: Jan Wilson, RN
630-634-1790

An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide versus Melphalan, Prednisone and Lenalidomide in Newly-Diagnosed Myeloma Patients who are not Candidates for High-Dose Therapy  [ECOG 1A06]

Principal Investigator
Renee Jacobs, MD
Contact: Terri Crestani
708-245-8158 

An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide versus Melphalan, Prednisone and Lenalidomide in Newly-Diagnosed Myeloma Patients who are not Candidates for High-Dose Therapy  [ECOG 1A06]

Principal Investigator:
Elyse Schneiderman, MD
Contact: Jan Wilson, RN
630-634-1790